Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free BCT Stock Alerts

BriaCell Therapeutics (BCT) Competitors

BriaCell Therapeutics logo
C$3.80 0.00 (0.00%)
As of 06/12/2026 03:59 PM Eastern
Compare

BCT vs. HBP, SCYB, COM, NVH, and IGX

Should you buy BriaCell Therapeutics stock or one of its competitors? MarketBeat compares BriaCell Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BriaCell Therapeutics include Helix BioPharma (HBP), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), and IntelGenx Technologies (IGX). These companies are all part of the "biotechnology" industry.

How does BriaCell Therapeutics compare to Helix BioPharma?

BriaCell Therapeutics (TSE:BCT) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

0.2% of BriaCell Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Helix BioPharma shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by company insiders. Comparatively, 2.2% of Helix BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Helix BioPharma's return on equity of -36.79% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
Helix BioPharma N/A -36.79%-279.98%

In the previous week, Helix BioPharma had 1 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for BriaCell Therapeutics. Helix BioPharma's average media sentiment score of 1.08 beat BriaCell Therapeutics' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the news media.

Company Overall Sentiment
BriaCell Therapeutics Neutral
Helix BioPharma Positive

BriaCell Therapeutics has a beta of 2.055007, meaning that its stock price is 106% more volatile than the broader market. Comparatively, Helix BioPharma has a beta of 0.421776, meaning that its stock price is 58% less volatile than the broader market.

Helix BioPharma is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.06N/A

Summary

BriaCell Therapeutics beats Helix BioPharma on 6 of the 10 factors compared between the two stocks.

How does BriaCell Therapeutics compare to Scythian Biosciences?

BriaCell Therapeutics (TSE:BCT) and Scythian Biosciences (CVE:SCYB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, BriaCell Therapeutics' average media sentiment score of 0.00 equaled Scythian Biosciences'average media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
Scythian Biosciences Neutral

Scythian Biosciences' return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
Scythian Biosciences N/A N/A N/A

0.2% of BriaCell Therapeutics shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
Scythian BiosciencesN/AN/AN/AN/AN/A

Summary

BriaCell Therapeutics and Scythian Biosciences tied by winning 2 of the 4 factors compared between the two stocks.

How does BriaCell Therapeutics compare to 138267 (COM.TO)?

BriaCell Therapeutics (TSE:BCT) and 138267 (COM.TO) (TSE:COM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

0.2% of BriaCell Therapeutics shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
138267 (COM.TO)N/AN/AN/AN/AN/A

In the previous week, BriaCell Therapeutics' average media sentiment score of 0.00 equaled 138267 (COM.TO)'saverage media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
138267 (COM.TO) Neutral

138267 (COM.TO)'s return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
138267 (COM.TO) N/A N/A N/A

Summary

BriaCell Therapeutics and 138267 (COM.TO) tied by winning 2 of the 4 factors compared between the two stocks.

How does BriaCell Therapeutics compare to Novoheart?

Novoheart (CVE:NVH) and BriaCell Therapeutics (TSE:BCT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

BriaCell Therapeutics has lower revenue, but higher earnings than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoheartC$423.50K236.08-C$7.17M-C$0.04N/A
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A

In the previous week, Novoheart's average media sentiment score of 0.00 equaled BriaCell Therapeutics'average media sentiment score.

Company Overall Sentiment
Novoheart Neutral
BriaCell Therapeutics Neutral

Novoheart's return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NovoheartN/A N/A N/A
BriaCell Therapeutics N/A -147.92%-122.71%

0.2% of BriaCell Therapeutics shares are owned by institutional investors. 9.3% of BriaCell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Novoheart and BriaCell Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does BriaCell Therapeutics compare to IntelGenx Technologies?

IntelGenx Technologies (CVE:IGX) and BriaCell Therapeutics (TSE:BCT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

BriaCell Therapeutics has lower revenue, but higher earnings than IntelGenx Technologies. IntelGenx Technologies is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IntelGenx TechnologiesC$1.75M49.95-C$11.74M-C$0.08N/A
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A

0.2% of BriaCell Therapeutics shares are owned by institutional investors. 9.3% of BriaCell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, IntelGenx Technologies' average media sentiment score of 0.00 equaled BriaCell Therapeutics'average media sentiment score.

Company Overall Sentiment
IntelGenx Technologies Neutral
BriaCell Therapeutics Neutral

IntelGenx Technologies' return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
IntelGenx TechnologiesN/A N/A N/A
BriaCell Therapeutics N/A -147.92%-122.71%

Summary

IntelGenx Technologies and BriaCell Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

Get BriaCell Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCT vs. The Competition

Export
MetricBriaCell TherapeuticsBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$33.06MC$445.47MC$6.52BC$12.19B
Dividend Yield13.70%3.88%2.67%6.19%
P/E Ratio-4.523.1824.0036.94
Price / SalesN/A6,471.80515.8410.45
Price / CashN/A13.1327.4882.29
Price / Book1.1887.8110.604.47
Net Income-C$2.37M-C$96.07MC$3.57BC$299.09M
7 Day Performance-11.21%-0.02%0.59%0.65%
1 Month Performance-7.99%-0.42%1.54%-0.08%
1 Year Performance-91.00%56.10%25.41%41.90%

BriaCell Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCT
BriaCell Therapeutics
N/AC$3.80
flat		N/A-91.0%C$33.06MN/AN/A16
HBP
Helix BioPharma
N/AC$1.52
+1.3%		N/AN/AC$116.10MN/AN/A9
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%		N/A+0.0%C$102.38MN/AN/AN/A
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/AN/AN/A
NVH
Novoheart
N/AC$0.53
+1.9%		N/A+0.0%C$99.98MC$423.50KN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:BCT) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel